

Please type a plus sign (+) inside this box → ☒

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/724,959
Filing Date	November 28, 2000
First Named Inventor	Dempsy, Robert O.
Group Art Unit	1634
Examiner Name	Chakrabarti
Attorney Docket Number	17682A-003610US

Total Number of Pages in This Submission

1

ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard References
--	---	---

RECEIVED

NOV 22 2002

TECH CENTER 1600/2900

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name	Townsend and Townsend and Crew LLP Joel G. Ackerman	Reg. No. 24,307
Signature		
Date	11/5/02	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date:

11-05-2002

Typed or printed name	Catherine Lindorfer		
Signature		Date	11-05-2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1403229 v1



FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180

Complete if Known

Application Number 09/724,959
Filing Date November 28, 2000
First Named Inventor Dempcy, Robert O.
Examiner Name Chakrabarti
Group Art Unit 1634
Attorney Docket No. 17682A-003610US

RECEIVED

NOV 22 2002

TECH CENTER 1600/2900

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ MoneyOrder ☐ Other ☐ None

☒ Deposit Account:

Deposit
Account
Number

20-1430

Deposit
Account
Name

Townsend and Townsend and Crew LLP

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments
☒ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	740	2001	370	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	510	2003	255	Plant filing fee	
1004	740	2004	370	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1)

(\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims		Fees from below		Fee Paid
Total Claims	-** =		X		=	
Independent Claims	-** =		X		=	
Multiple Dependent			X		=	

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2)

(\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	400	2252	200	Extension for reply within second month	
1253	920	2253	460	Extension for reply within third month	
1254	1,440	2254	720	Extension for reply within fourth month	
1255	1,960	2255	980	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,280	2453	640	Petition to revive - unintentional	
1501	1,280	2501	640	Utility issue fee (or reissue)	
1502	460	2502	230	Design issue fee	
1503	620	2503	310	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Petitions related to provisional applications	
1806	180	1806	180	Submission of Information Disclosure Stmt	180
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	740	2809	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	740	2810	370	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	740	2801	370	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid SUBTOTAL (3)

(\$180)

SUBMITTED BY


Complete (if applicable)

Name (Print/Type) Joel G. Ackerman Registration No. (Attorney/Agent) 24,307 Telephone 415-576-0200

Signature Date 11/5/02

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. SF 1403205 v1



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

PATENT
Attorney Docket No.: 17682A-003610US
Client Reference No.: 152A

#13

RECEIVED

NOV 22 2002

TECH CENTER 1600/2900

On November 5, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Cathy Lindorf

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Robert O. DEMPCY et al.

Application No.: 09/724,959

Filed: November 28, 2000

For: MODIFIED
OLIGONUCLEOTIDES FOR
MISMATCH DISCRIMINATION

Examiner: Chakrabarti, Arun

Art Unit: 1634

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.

Also enclosed is a copy of the Search Report in a corresponding PCT application.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Joel G. Ackerman
Reg. No. 24,307

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
JA:cjl



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

6

Complete if Known

Application Number	09/724,959
Filing Date	November 28, 2000
First Named Inventor	Dempcy, Robert O.
Art Unit	1634
Examiner Name	Chakrabarti
Attorney Docket Number	17682A-003610US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	A1	09/457,616	Filed 12-08-1999	Reed et al.	
	A2	6,339,147 B1	01-15-2002	Lukhtanov et al.	
	A3	6,312,894 B1	11-06-2001	Hedgpeth et al.	
	A4	3,996,345	12-07-1976	Ullman et al.	
	A5	4,351,760	09-28-1982	Khanna et al.	
	A6	4,358,535	11-09-1982	Falkow et al.	
	A7	4,683,195	07-28-1987	Mullis et al.	
	A8	4,683,202	07-28-1987	Mullis	
	A9	4,800,159	01-24-1989	Mullis et al.	
	A10	4,868,105	09-19-1989	Urdea et al.	
	A11	5,124,246	06-23-1992	Urdea et al.	
	A12	5,177,196	01-05-1993	Meyer, Jr. et al.	
	A13	5,210,015	05-11-1993	Gelfand et al.	
	A14	5,419,966	05-30-1995	Reed et al.	
	A15	5,449,767	09-12-1995	Ward et al.	
	A16	5,484,908	01-16-1996	Froehler et al.	
	A17	5,492,806	02-20-1996	Drmanac et al.	
	A18	5,512,667	04-30-1996	Reed et al.	
	A19	5,525,464	06-11-1996	Drmanac et al.	
	A20	5,556,749	09-17-1996	Mitsuhashi et al.	
	A21	5,556,752	09-17-1996	Lockhart et al.	
	A22	5,585,481	12-17-1996	Arnold, Jr., et al.	
	A23	5,645,985	07-08-1997	Froehler et al.	
	A24	5,696,251	12-09-1997	Arnold, Jr. et al.	
	A25	5,736,626	04-07-1998	Mullah et al.	
	A26	5,801,155	09-01-1998	Kutyavin et al.	
	A27	5,824,796	10-20-1998	Petrie et al.	
	A28	5,942,610	08-24-1999	Nelson et al.	
	A29	6,127,121	10-03-2000	Meyer, Jr. et al.	
	A30	5,849,482	12-15-1998	Meyer, Jr. et al.	

RECEIVED

NOV 22 2002

TECH CENTER 1600/2900

Examiner
Signature


Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1403063 v1



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **6**

Complete if Known

Application Number	09/724,959
Filing Date	November 28, 2000
First Named Inventor	Dempcy, Robert O.
Art Unit	1634
Examiner Name	Chakrabarti
Attorney Docket Number	17682A-003610US

TECH CENTER 600/2900

NOV 22 2002

RECEIVED

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	WO	96/32496		10-17-1996	Microprobe Corporation		
	B2	WO	92/10588		06-25-1992	Affymax Technologies N.V.		
	B3	WO	96/17957		06-13-1996	Hyseq, Inc.		
	B4	WO	99/37085		07-22-1999	Comsat Corporation		
	B5	WO	99/51775		10-14-1999	Epoch Pharmaceuticals Inc.		
	B6	WO	98/49180		11-05-1998	Epoch Pharmaceuticals Inc.		
	B7	WO	99/51621		10-14-1999	Epoch Pharmaceuticals Inc.		
	B8	WO	90/03370		05-05-1990	Microprobe Corporation		
	B9	WO	00/06771		02-10-2000	Affymetrix, Inc.		
	B10	WO	97/46313		12-11-1997	Array Technologies		


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
SF 1403063 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **3** of **6**

Complete if Known

Application Number	09/724,959
Filing Date	November 28, 2000
First Named Inventor	Dempcy, Robert O.
Art Unit	1634
Examiner Name	Chakrabarti
Attorney Docket Number	17682A-003610US

TECH CENTER 1600/2900

NOV 22 2002

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	ALLAWI, Hatim T. et al., "Thermodynamics and NMR of Internal G-T Mismatches in DNA", <i>Biochemistry</i> , Vol. 36:10581-10595 (1997)	
	C2	BALOW, Guity et al., "Biophysical and antisense properties of oligodeoxynucleotides containing 7-propynyl-, 7-iodo- and 7-cyano-7-deaza-2-amino-2'-deoxyadenosines", <i>Nucleic Acids Research</i> , Vol. 26, No. 14:3350-3357 (1998)	
	C3	BEAUCAGE, Serge L. et al., "Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach", <i>Tetrahedron Report Number 309</i> Vol. 48, No. 12:2223-2311 (1992), Pub. in Great Britain	
	C4	BLAKE, R.D. et al., "Statistical mechanical simulation of polymeric DNA melting with MELTSIM", <i>Bioinformatics</i> , Vol. 15, No. 5, 370-5 (1999)	
	C5	BOLLI, Martin et al., "Watson-Crick base-pairing properties of bicyclo-DNA", <i>Nucleic Acids Research</i> , Vol. 24, No. 23:4660-4667 (1996) -- Oxford University Press	
	C6	CAPALDI, Stephen et al., "Signal amplification through nucleotide extension and excision on a dendritic DNA platform", <i>Nucleic Acids Research</i> , Vol. 28, No. 7:E21 (2000) -- Oxford University Press	
	C7	CHEN, Jer-Kang et al., "Synthesis of oligodeoxyribonucleotide N3'→P5' phosphoramidates" <i>Nucleic Acids Research</i> , Vol. 23, No. 14:2661-2668 (1995) -- Oxford University Press	
	C8	DRAPER, David E. et al. "A Method for Linking Fluorescent Labels to Polynucleotides: Application to Studies of Ribosome--Ribonucleic Acid Interactions", <i>Biochemistry</i> Vol. 19:1774-1781 (1980) -- American Chemical Society	
	C9	EISEN, Michael B., et al., "DNA Arrays for Analysis of Gene Expression", <i>Methods In Enzymology</i> , Vol. 303:179-205 (1999) -- Academic Press	
	C10	FLANAGAN, W. Michael et al., "Elucidation of gene function using C-5 propyne antisense oligonucleotides", <i>Nature Biotechnology</i> , Vol. 14:1139-1145 (1996)	
	C11	GIESEN, Ursula et al., "A formula for thermal stability (T_m) prediction of PNA/DNA duplexes" <i>Nucleic Acids Research</i> , Vol. 26, No. 21:5004-5006 (1998) -- Oxford University Press	
	C12	GUETENS, G. et al., "Nanotechnology in bio/clinical analysis", <i>Journal of Chromatography B. Biomed. Sci. Appl.</i> Vol. 739:139-150 (2000) -- Elsevier Science B.V.	
	C13	HACIA, Joseph G. et al., "Mutational analysis using oligonucleotide microarrays", <i>J. Mol. Genet.</i> , Vol. 36:730-736 (1999)	
	C14	HALL, Jeff G. et al., "Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction", <i>PNAS</i> Vol. 97, No. 15:8272-77 (2000)	
	C15	HEID, Christian A. et al. "Real Time Quantitative PCR", <i>Genome Research</i> Vol. 6:986-994 (1996) -- Cold Spring Harbor Laboratory Press	
	C16	LIVAK, Kenneth J. et al., "Oligonucleotides with Fluorescent Dyes at Opposite Ends Provide a Quenched Probe System Useful for Detecting PCR Product and Nucleic Acid Hybridization", <i>PCR Methods and Applications</i> Vol. 4:357-362 (1995) -- Cold Spring Harbor Laboratory Press	

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1403063 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **4** of **6**

Complete if Known

Application Number	09/724,959
Filing Date	November 28, 2000
First Named Inventor	Dempcy, Robert O.
Art Unit	1634
Examiner Name	Chakrabarti
Attorney Docket Number	17682A-003610US

TECH CENTER 600/2900

NOV 22 2002

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C17	LOHKOV, S.G., "Thermodynamic and spectral properties of DNA miniduplexes with the terminal G-A mispairs and 3' or 5' dangling bases", <i>FEBS Letters</i> Vol. 420:134-138 (1997) -- Federation of European Biochemical Societies	
	C18	LYAMICHEV, Victor et al., "Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes", <i>Nature Biotechnology</i> , Vol. 17:292-296 (1999)	
	C19	MUELLER, James D. et al, "Self-sustained sequence replication (3SR): an alternative to PCR", <i>Histochem. Cell Biol.</i> , Vol. 108:431-437 (1997) -- Springer-Verlag	
	C20	NIELSEN, Peter E. et al., "Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide" <i>Science</i> , Vol. 254:1497-1500 (1991)	
	C21	OWCZARZY, Richard et al, "Predicting Sequence-Dependent Melting Stability of Short Duplex DNA Oligomers", <i>Biopolymers "Sequence-Dependent Melting Stability"</i> , Vol. 44:217-239 (1997) -- John Wiley & Sons, Inc. 1998	
	C22	PALISSA, Manfred et al., Reduktion geschützter 2'-Chlor-2'-desoxydinucleotide mit Tri-n-butylzinnhydrid", <i>Z. Chem.</i> , Vol. 27:216 (1987)	
	C23	PASTINEN, Tom et al., "A System for Specific, High-throughput Genotyping by Allele-specific Primer Extension on Microarrays", <i>Genome Research</i> , Vol. 10:1031-42 (2000) -- Cold Spring Harbor Laboratory Press	
	C24	RAMZAEVA, Natalya et al., "123. 7-Deazaguanine DNA: Oligonucleotides with Hydrophobic or Cationic Side Chains", <i>Helvetic Chimica. Acta</i> , Vol. 80:1809-1822 (1997)	
	C25	REDDY, B.S. Praveen et al., "Synthetic DNA minor groove-binding drugs", <i>Pharmacolgy & Therapeutics</i> , Vol. 84:1-111 (1999) -- Elsevier Science Inc.	
	C26	SCHÜTZ, Ekkehard et al., "Spreadsheet Software for Thermodynamic Melting Point Prediction of Oligonucleotide Hybridization with and without Mismatches" <i>BioTechniques</i> , Vol. 27, No. 6:1218-22 (1999)	
	C27	SEELA, Frank et al., "Synthesis of oligonucleotides containing pyrazolo [3,4-d]-pyrimidines: The influence of 7-substituted 8-aza-7-deazaadenines on the duplex structure and stability", <i>J. Chem. Soc. Perkin Trans.</i> , Vol. 1:479-488 (1999)	
	C28	SEELA, Frank et al., "The N ⁸ -(2'-deoxyribofuranoside) of 8-aza-7-deazaadenine: a universal nucleoside forming specific hydrogen bonds with the four canonical DNA constituents", <i>Nucleic Acids Research</i> , Vol. 28, No. 17:3224-3232 (2000) -- Oxford Univeristy Press	
	C29	SINGH, Sanjay et al, "LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition", <i>Chem. Comm.</i> , 455-456 (1998)	
	C30	SMITH, C.C. et al, "Modified adenovirus penton base protein (UTARVE) as a non-replicating vector for delivery of antisense oligonucleotides with antiviral and/or antineoplastic activity", <i>International Journal of Oncology</i> , Vol. 17:841-850 (2000)	
	C31	SUGIMOTO, Naoki et al., "Thermodynamic Parameters To Predict Stability of RNA/DNA Hybrid Duplexes", <i>Biochemistry</i> Vol. 34, No. 35:11211-11216 (1995) -- American Chemical Society	
	C32	TATON, T. Andrew et al, "Scanometric DNA Array Detection with Nanoparticle Probes", <i>Science</i> Vol. 289:1757-1760 (2000)	


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1403063 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **5** of **6**

Complete if Known

Application Number	09/724,959
Filing Date	November 28, 2000
First Named Inventor	Dempcy, Robert O.
Art Unit	1634
Examiner Name	Chakrabarti
Attorney Docket Number	17682A-003610US

TECH CENTER 1600/2900

NOV 28 2002

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C33	TAYLOR, Edward C. et. al., "Synthesis of Pyrazolo[3,4-d]pyrimidine Analogues of the Potent Antitumor Agent N-{4-[2-(2-Amino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethy1]benzoy1}-L-glutamic Acid (LY231514) <i>Tetrahedron</i> , Vol. 48, No. 37:8089-8100 (1992) -- Pergamon Press Ltd.	
	C34	UHLMANN, Eugen et al., "Antisense Oligonucleotides: A New Therapeutic Principle", <i>Chemical Reviews</i> , Vol. 90, No. 4:543-584 (1990) -- American Chemical Society	
	C35	UHLMANN, Eugen et al., "PNA: Synthetic Polyamide Nucleic Acids with Unusual Binding Properties", <i>Angew. Chem. Int. Ed.</i> 37:2796-2823 (1998) -- WILEY-VCH Verlag GmbH, D-69451 Weinheim, 1998	
	C36	VAN NESS, Jeffrey et al., "A versatile solid support system for oligodeoxynucleotide probe-based hybridization assays", <i>Nucleic Acids Research</i> Vol. 19, No. 12:5143-5151 (1991) -- Oxford University Press	
	C37	VINCENT, Stéphane et al, "Hydrolysis and Hydrogenolysis of Formamides: N,N-Dimethyl and N,N-Dibenzyl Formamides as Protective Groups for Primary Amines", <i>J. Org. Chem.</i> , Vol. 64, No. 3:991-997 (1999) -- American Chemical Society	
	C38	WALKER, Wynn L. et al., "Progress in the Design of DNA Sequence-Specific Lexitropsins", <i>Biopolymers</i> , Vol. 44:323-334 (1997)	
	C39	WEMMER, David E. et al., "Targeting the minor groove of DNA", <i>Current Opinon in Structural Biology</i> , Vol. 7:355-361 (1997)	
	C40	WENGEL, Jesper, "Sythesis of 3'-C- and 4'-C-Branched Oligodeoxynucleotides and the Development of Locked Nucleic Acid (LNA)", <i>Acc. Chem. Res.</i> , Vol. 32:301-310 (1998) -- American Chemical Society	
	C41	ZHANG, Hong et al, "Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis", <i>Nature Biotechnology</i> , Vol. 18:862-867 (2000) -- Nature America Inc.	
	C42	ZIMMER, Christoph et al., "Nonintercalating DNA-Binding Ligands: Specificity of the Interaction and Their Use As Tools in Biophysical, Biochemical and Biological Investigations of the Genetic Material", <i>U. Prog. Biophys. Molec. Bio.</i> Vol. 47:31-112 (1986) -- Pergamon Press Ltd.	
	C43	SEELA, F. et al. "8-AZA-7-Deazapurine DNA: Synthesis And Duplex Stability Of Oligonucleotides Containing 7-Substituted Bases," <i>Nucleosides & Nucleotides</i> , 18(6&7):1399-1400 (1999)	
	C44	SEELA, F. et al. "Oligonucleotides Containing Pyrazolo [3,4-d] pyrimidines: The Influence of 7-Substituted 8-Aza-7-deaza-2'-deoxyguanosines on the Duplex Structure and Stability," <i>Helvetica Chimica Acta</i> , Vol. 82:1640-1655 (1999)	
	C45	SEELA, F. et al. "Duplex Stability Of Oligonucleotides Containing 7-Substituted 7-DEAZA- AND 8-AZA-7-Deazapurine Nucleosides," <i>Nucleosides & Nucleotides</i> , 16(7-9):963-966 (1997)	
	C46	SEELA, F. et al. "131. 8-Aza-7-deaza-2'-deoxyguanosine: Phosphoramidite Synthesis and Properties of Octanucleotides," <i>Helvetica Chimica Aca</i> , Vol. 71:1191-1197 (1988)	
	C47	SEELA, F. et al. "The Influence of Modified Purine Bases on the Stability of Parallel DNA," <i>Bioorganic & Medicinal Chemistry Letters</i> , 10:289-292 (2000)	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1403063 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **6** of **6**

Complete if Known

Application Number	09/724,959
Filing Date	November 28, 2000
First Named Inventor	Dempcy, Robert O.
Art Unit	1634
Examiner Name	Chakrabarti
Attorney Docket Number	17682A-003610US

TECH CENTER 1600/2900

NOV 22 2002

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C48	SEELA, F. et al. "Synthesis of 7-alkynylated 8-aza-7-deaza-2'-deoxyadenosines via the Pd-catalysed cross-coupling reaction," <i>J. Chem. Soc., Perkin Trans.</i> , 1:3233-3239 (1998)	
	C49	GRAHAM, D. et al. "DNA duplexes stabilized by modified monomer residues: synthesis and stability," <i>J. Chem. Soc., Perkin Trans.</i> , 1:1131-1138 (1998)	
	C50	HOBBS, F. W., Jr. "Palladium-Catalyzed Synthesis of Alkynylamino Nucleosides. A Universal Linker for Nucleic Acids," <i>J. Org. Chem.</i> , 54:3420-3422 (1989)	
	C51	CRUICKSHANK, K.A. et al. "Oligonucleotide Labelling: A Concise Synthesis Of A Modified Thymidine Phosphoramidite," <i>Tetrahedron Letters</i> , Vol. 29 No. 41, pp 5221-5224 (1988)	
	C52	ROBINS, M.J. et al. "Nucleic Acid Related Compounds. 39. Efficient Conversion of 5-Iodo to 5-Alkynyl and Derived 5-Substituted Uracil Bases and Nucleosides," <i>J. Org. Chem.</i> , 48:1854-1862 (1983)	
	C53	CLERCQ, E.D. et al. "Nucleic Acid Related Compounds. 40. Synthesis and Biological Activities of 5-Alkynyluracil Nucleosides," <i>Journal of Medicinal Chemistry</i> , Vol. 26, No. 5:661-666 (1983)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1403063 v1